Drug Trial Radar · NCT04730258
A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML
Last checked: Nov 20, 2026Latest source record: May 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Apr 16, 2021
Primary completion
Jan 2026
Study completion Jan 2026
Sponsor
- Lead sponsor
- Treadwell Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Jan 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to test the safety of an investigational drug called CFI-400945 alone and in combination with azacitidine.
Conditions
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia
- AML
- MDS
- CMML
Interventions
CFI-400945Drug
The starting dose is 32 mg/day for escalation arms and the recommended starting dose for the expansion arms.
AzacitidineDrug
Azacitidine will be given at its labeled dose and schedule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment emergent AEsTime frame: 36 months
- Treatment emergent changes in vital signsTime frame: 36 months
- Treatment emergent changes in clinical laboratory testsTime frame: 36 months
- Treatment emergent changes in physical examinations, ECOG performance status, electrocardiograms (ECGs), echocardiograms and cardiac troponinsTime frame: 36 months
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Norton Cancer Institute - Saint Matthews
Louisville, Kentucky
New York Presbyterian Weill Cornell Medical Center
New York, New York
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio
The University of Texas MD Anderson Cancer Centre
Houston, Texas
University of Alberta
Edmonton, Alberta, Canada
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Queen Mary Hospital
Hong Kong, Hong Kong
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.